ALNY
Alnylam Pharmaceuticals Inc
219.70$
-5.0%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -41.4% | +12.4% | +33.5% | -24.1% | +18.4% | +0.2% | +30.2% | +61.4% | -12.2% | +6.4% | +10.6% | – | |
| – | +1.8% | -23.2% | +4.1% | +25.1% | +19.7% | -30.9% | +101.2% | +38.0% | +35.7% | -21.1% | +41.3% | – | |
| – | -46.9% | +21.1% | +38.0% | -29.8% | +18.2% | +6.7% | +20.6% | +66.8% | -21.2% | +15.3% | +3.8% | – | |
| – | +7.5% | -4.1% | +12.7% | -7.9% | +10.8% | -11.7% | +22.1% | +10.9% | +3.7% | -2.0% | +13.2% | – | |
| – | -0.5% | +6.4% | +17.8% | -11.0% | +33.6% | -18.8% | +34.7% | -0.4% | +1.0% | -0.9% | +7.9% | – | |
| – | +4.0% | +0.3% | +15.0% | -9.3% | +21.1% | -15.2% | +28.1% | +5.7% | +2.0% | -1.5% | +10.7% | – | |
| – | -154.4% | – | – | -258.2% | – | – | -189.6% | – | -64.2% | +103.9% | -13.8% | – | |
| – | +1.4% | +12.5% | -5.7% | +3.4% | +13.4% | -0.8% | +4.1% | +10.3% | +191.3% | -46.4% | +18.4% | – | |
| – | -191.3% | – | – | – | – | – | – | – | -32.6% | +37.6% | -19.8% | – | |
| – | -93.9% | +1,183.1% | +143.7% | -49.2% | -3,890.7% | – | +94.7% | -139.2% | – | – | – | – | |
| – | -193.3% | – | – | – | – | – | – | – | -25.8% | +10.5% | -20.1% | – | |
| – | -147.6% | – | – | -262.6% | – | – | +64.4% | +1,478.0% | +2.3% | +0.2% | -19.6% | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.